{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:24:16Z","timestamp":1785864256215,"version":"3.56.0"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Data on switching to bictegravir, emtricitabine, and tenofovir alafenamide (B\/F\/TAF) in virologically suppressed Asian people living with HIV are limited. We performed a pooled analysis of virologically suppressed Asian participants from three international phase III trials to evaluate the efficacy and safety of switching to B\/F\/TAF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Virologically suppressed people living with HIV were randomized to switch to B\/F\/TAF or to stay on baseline regimens. The primary endpoint was the proportion of participants with plasma HIV\u20101 RNA \u226550 copies\/ml at week 48. We analysed the incidence of adverse events (AEs), laboratory abnormalities, and changes in relevant tolerability parameters through 48\u2009weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 136 Asian participants were included. The proportions of participants with plasma HIV\u20101 RNA \u226550\u2009copies\/ml at week 48 were low in both arms (0% for B\/F\/TAF vs 1.4% for those who stayed on baseline regimens). Those who switched to B\/F\/TAF had virological suppression rates similar to those who stayed on baseline regimens (100% vs 95.9%, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.2485), with no treatment\u2010emergent resistance. Drug\u2010related AEs occurred in three participants in each arm; none were serious. No participants discontinued the study drug because of AEs, and no deaths were observed. No significant differences were observed between the arms in the median changes in estimated glomerular filtration rate, body weight, and most lipid parameters. Switching from tenofovir disoproxil fumarate\u2010containing regimens to B\/F\/TAF resulted in a significant decrease in tubular proteinuria compared with those who stayed on baseline regimens (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Virologically suppressed Asian people living with HIV who switched to B\/F\/TAF maintained 100% virological suppression at week 48, with no treatment\u2010emergent drug resistance and safety profiles comparable to those seen in people who stayed on baseline regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Number<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> (NCT02603120, NCT02652624, and NCT02603107).<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.13386","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T01:13:15Z","timestamp":1660785195000},"page":"290-300","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3222-9611","authenticated-orcid":false,"given":"Anchalee","family":"Avihingsanon","sequence":"first","affiliation":[{"name":"HIV\u2010NAT, Thai Red Cross AIDS Research Centre  Bangkok Thailand"},{"name":"Centre of Excellence in Tuberculosis, Faculty of Medicine Chulalongkorn University  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ploenchan","family":"Chetchotisakd","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Khon Kaen University  Khon Kaen Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4379-4704","authenticated-orcid":false,"given":"Sasisopin","family":"Kiertiburanakul","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Ramathibodi Hospital Mahidol University  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winai","family":"Ratanasuwan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Siriraj Hospital Mahidol University  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krittaecho","family":"Siripassorn","sequence":"additional","affiliation":[{"name":"Bamrasnaradura Infectious Diseases Institute  Nonthaburi Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khuanchai","family":"Supparatpinyo","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Chiang Mai University  Chiang Mai Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hal","family":"Martin","sequence":"additional","affiliation":[{"name":"Gilead Sciences  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Gilead Sciences  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TinHung","family":"Wong","sequence":"additional","affiliation":[{"name":"Gilead Sciences  Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiu Yin","family":"Wang","sequence":"additional","affiliation":[{"name":"Gilead Sciences  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1010-7"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32340-1"},{"key":"e_1_2_11_4_1","volume-title":"Guidelines version 10.1","author":"EACS","year":"2020"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17025"},{"key":"e_1_2_11_6_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in adults and adolescents with HIV2021;Available from:http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf."},{"key":"e_1_2_11_7_1","unstructured":"New data show switching to Biktarvy regimen beneficial in Asian population.2020Available from:https:\/\/www.thepharmaletter.com\/article\/new\u2010data\u2010show\u2010switching\u2010to\u2010biktarvy\u2010regimen\u2010beneficial\u2010in\u2010asian\u2010population."},{"key":"e_1_2_11_8_1","unstructured":"Taiwan AIDS Society.Guidelines for the Diagnosis and Treatment of AIDS2020."},{"key":"e_1_2_11_9_1","unstructured":"UNAIDS.Regional factsheets: Asia and Pacific 2020.2021. Available from:https:\/\/aidsinfo.unaids.org\/."},{"key":"e_1_2_11_10_1","unstructured":"World Health Organization.Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection2016."},{"issue":"12","key":"e_1_2_11_11_1","first-page":"867","article-title":"Zhonghua Nei Ke Za Zhi","volume":"57","author":"Chinese guidelines for diagnosis and treatment of HIV\/AIDS","year":"2018","journal-title":"Chin J Intern Med"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30077-3"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30099-0"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30080-3"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30092-4"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002137"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30091-2"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022661"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000347"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2014.08.015"},{"key":"e_1_2_11_22_1","unstructured":"ClinicalTrials.gov.Identifier NCT02603120 Safety and Efficacy of Switching From Dolutegravir and ABC\/3TC or ABC\/DTG\/3TC to B\/F\/TAF in HIV\u20101 Infected Adults Who Are Virologically Suppressed2020. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02603120."},{"key":"e_1_2_11_23_1","unstructured":"ClinicalTrials.gov.Identifier NCT02652624 Safety and Efficacy of Switching to a FDC of B\/F\/TAF From E\/C\/F\/TAF E\/C\/F\/TDF or ATV+RTV+FTC\/TDF in Virologically Suppressed HIV\u20101 Infected Women2020. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02652624."},{"key":"e_1_2_11_24_1","unstructured":"ClinicalTrials.gov.Identifier NCT02603107 Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine\/Tenofovir or Abacavir\/Lamivudine to Bictegravir\/Emtricitabine\/Tenofovir Alafenamide in Virologically Suppressed HIV\u20101 Infected Adults2020. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02603107."},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/009286151104500309"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa125"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833ad8b4"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12833"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz999"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.07.030"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa177"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab444"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy083"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31065-5"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1073"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13386","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.13386","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13386","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:19:32Z","timestamp":1692663572000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.13386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1111\/hiv.13386"],"URL":"https:\/\/doi.org\/10.1111\/hiv.13386","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]},"assertion":[{"value":"2022-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}